Antitumor antibiotic derived from Streptomyces caespitosus; widely used for treatment and prevention of superficial bladder cancer (intravesical instillation).
Cutaneous side-effect: 9% of patients treated with intravesical instillations.
Risk factors
Association with vincristine, bleomycin or doxorubicin.
Clinical manifestations
Cutaneous: vesicular dermatitis of the hands, the genitals, and feet. More diffuse reactions involving the trunk.
Respiratory: interstitial lung disease.
Diagnostic methods
Cutaneous testing.
Skin tests: one immediately positive intradermal skin test reported in a patient who presented an immediate reaction.
Patch-tests (concentration ranging from 0.06% to 0.6% in water or in petrolatum) positive in patients with contact allergy.
Presence of CD I + has been shown in bladder epithelium.
Eczematous eruptions are type IV hypersensitivity reactions; mediated transvesically.
Topical corticosteroids may be useful.


  1. de Groot A.C, Conemans J.M, "Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C", Contact. Dermatitis., 1991; 24 (3): 201-9
  2. Colver G.B, Inglis J.A, Mc Vittie E, Spencer M.J, Tolley D.A, Hunter J.A, "Dermatitis due to intravesical mitomycin C: a delayed-type hypersensitivity reaction ?", Br. J. Dermatol., 1990; 122 (2): 217-24
  3. Nissenkorn I, Herrod H, Soloway M.S, "Side effects associated with intravesical mitomycin", J. Urol., 1981; 126 (5): 596-7

As in all diagnostic testing, the diagnosis is made by the physican based on both test results and the patient history.